Osteoporosis
📧 Sign up to get email alerts when something new happens for Osteoporosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Kauliv (teriparatide) — Strides Pharma (Cyprus) Limited
Kauliv (teriparatide) has been authorised by the EMA for osteoporosis-related indications, including postmenopausal osteoporosis, by Strides…
-
EMA approval · 2026-08-24EMA Authorised: Izamby (denosumab) — Mabxience Research SL
EMA authorises Izamby (denosumab) for bone resorption disorders including osteoporosis and postmenopausal osteoporosis.
-
EMA approval · 2026-08-20EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
Authorisation of Junod (denosumab) by Gedeon Richter Plc. for conditions related to bone resorption and osteoporosis, including postmenopaus…
-
EMA approval · 2026-08-19EMA Authorised: Prolia (denosumab) — Amgen Europe B.V.
EMA authorises Prolia (denosumab) for osteoporosis-related indications, confirming market approval in the European Union.
-
EMA approval · 2026-08-18EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence (denosumab) for osteoporosis indications, including postmenopausal osteoporosis and bone resorption conditions.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-04EMA Authorised: Obodence (denosumab) — Samsung Bioepis NL B.V.
Obodence (denosumab) has been authorised in the EU for osteoporosis and related bone resorption indications.
-
EMA approval · 2026-07-17EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
The EMA has authorised Kefdensis (denosumab) by Stada Arzneimittel AG for conditions related to bone resorption and osteoporosis, including …
-
EMA approval · 2026-07-14EMA Authorised: Bildyos (denosumab) — Sciencepharma Sp. z o.o
The EMA has authorised Bildyos (denosumab) by Sciencepharma Sp. z o.o. for bone resorption disorders including osteoporosis, including postm…
-
EMA approval · 2026-07-14EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH
EMA authorised Acvybra (denosumab) for osteoporosis-related indications in Europe, with Reddy Holding GmbH as MAH.
-
EMA approval · 2026-07-09EMA Authorised: Evenity (romosozumab) — UCB Pharma S.A.
Evenity (romosozumab) has been authorised in the EU for osteoporosis. The marketing authorisation holder is UCB Pharma S.A.
-
EMA approval · 2026-06-16EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
Authorised status for Kefdensis (denosumab) by Stada Arzneimittel AG for bone resorption disorders including osteoporosis and postmenopausal…
-
EMA approval · 2026-04-24EMA Authorised: Vysribli (previously Denosumab Intas) (denosumab) — Intas Third Party Sales 2005 S.L.
EMA authorised Vysribli (denosumab) for osteoporosis indications, including postmenopausal osteoporosis, with MAH Intas Third Party Sales 20…
-
EMA approval · 2026-04-23EMA Authorised: Terrosa (teriparatide) — Gedeon Richter Plc.
The EU authorised Terrosa, a teriparatide product by Gedeon Richter, for osteoporosis.
-
EMA approval · 2026-04-22EMA Authorised: Movymia (teriparatide) — STADA Arzneimittel AG
The EMA authorised Movymia, a teriparatide product by STADA Arzneimittel AG, for the treatment of osteoporosis in the EU.
-
EMA approval · 2026-04-20EMA Authorised: Aclasta (zoledronic acid) — Sandoz Pharmaceuticals d.d.
The EMA authorised Sandoz's Aclasta (zoledronic acid) for osteoporosis indications, including postmenopausal osteoporosis and Paget disease …
-
FDA approval · 2026-04-15FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM submitted by Aurobindo Pharma Limited.
-
EMA approval · 2026-03-31EMA Authorised: Zoledronic acid Mylan (zoledronic acid) — Mylan Pharmaceuticals Limited
The European Medicines Agency authorised Zoledronic acid Mylan (zoledronic acid) for bone/fracture indications. The product is manufactured …
-
EMA approval · 2026-03-23EMA Authorised: Sondelbay (teriparatide) — Accord Healthcare S.L.U.
EMA authorised Sondelbay (teriparatide) by Accord Healthcare S.L.U. for osteoporosis, marking EU marketing authorisation. Decision date: 23/…
-
EMA approval · 2026-03-20EMA Authorised: Evfraxy (denosumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Evfraxy (denosumab) as a biosimilar; it is approved for bone resorption disorders including osteoporosis and postmenopausal o…
-
EMA approval · 2026-03-04EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG
The European Medicines Agency authorised Kefdensis, a denosumab medicine by STADA Arzneimittel AG, for osteoporosis indications including po…
-
FDA approval · 2026-03-04FDA Approved: CALCITONIN SALMON — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves Zydus Pharmaceuticals USA Inc.'s Original Application for Calcitonin Salmon, a generic version of the established drug. This ap…
-
EMA approval · 2026-02-26EMA Authorised: Conexxence (denosumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Conexxence, a denosumab product from Fresenius Kabi Deutschland GmbH, for osteoporosis including postmenopausal osteoporosis.…
-
EMA approval · 2026-02-24EMA Authorised: Acvybra (denosumab) — Reddy Holding GmbH
The European Medicines Agency has authorised Acvybra (denosumab) from Reddy Holding GmbH for osteoporosis-related conditions, including post…
-
EMA approval · 2026-02-24EMA Authorised: Zoledronic Acid Accord (zoledronic acid monohydrate) — Accord Healthcare S.L.U.
The EMA authorised Zoledronic Acid Accord (zoledronic acid monohydrate) for hypercalcemia, prevention of fractures in bone disorders, and ca…
-
EMA approval · 2026-02-12EMA Authorised: Fosavance (alendronic acid;colecalciferol) — Organon N.V.
EMA authorised Fosavance (alendronic acid and colecalciferol) by Organon N.V. for osteoporosis, including postmenopausal osteoporosis.